All articles tagged with #rap1
A Science Advances study in mice shows metformin lowers glucose via brain Rap1 signaling in the ventromedial hypothalamus, not just liver or gut; deleting Rap1 in this brain region abolishes metformin’s effect, while direct brain administration also lowers glucose, suggesting brain-targeted mechanisms could unlock new diabetes therapies and possibly aging benefits.
Scientists have found that metformin not only acts in the liver and gut but also operates in the brain, where it suppresses the RAP1 protein in a hypothalamic region to activate glucose-lowering neurons, potentially enabling brain-targeted diabetes therapies at very low doses.
Researchers find metformin lowers blood sugar by acting in the brain, specifically by suppressing Rap1 in the ventromedial hypothalamus to activate SF1 neurons. These effects occur at tiny brain doses, suggesting a brain pathway adds to the drug’s known liver and gut actions and could inspire new diabetes therapies and broadened understanding of metformin’s brain benefits.
Rivian’s R2 is designed to move the brand into mass‑market EVs, with a four‑trim lineup planned through 2027. The launch Performance model starts at about $57,990 (roughly $59,485 with destination) delivering 656 hp, 609 lb‑ft, 0–60 in 3.6 seconds, and about 330 miles of range; the lineup later adds a Standard Long Range and a base Standard model, with a target $45k price in late 2027. Early R2s will use Gen 2 RAP1 hardware (no lidar, no Level 3 autonomy yet) but Rivian plans Gen 3 hardware later, plus a 29‑minute 10–80% charge on NACS chargers. The goal is higher sales and better cash flow, though early tech and cost‑cutting choices mean some features will arrive after launch.
Scientists discovered that metformin lowers blood sugar not only via the liver and gut but also by acting in the brain. In mice, metformin inhibits Rap1 in the ventromedial hypothalamus, activating SF1 neurons and reducing glucose; surprisingly small brain doses produced effects, and removing Rap1 from VMH abolished metformin’s action, illustrating a distinct brain pathway that could enable lower-dose, brain-targeted diabetes therapies in the future.
Scientists reveal metformin lowers blood sugar by acting in the brain, specifically by suppressing Rap1 in the ventromedial hypothalamus and activating SF1 neurons, with brain effects at far lower drug levels than previously thought, opening possibilities for brain-targeted diabetes therapies and potential brain-health benefits.
New research shows metformin can act in the brain, reaching the ventromedial hypothalamus and inhibiting Rap1 signaling in SF1 neurons to help regulate glucose in mice, a mechanism distinct from its liver and gut effects. When Rap1 was removed, metformin no longer helped diabetes-like symptoms, suggesting a brain pathway. This could lead to brain-targeted diabetes therapies and broaden metformin’s uses, though human studies are needed and side effects like GI distress and kidney risk remain concerns; the drug is also linked to aging benefits.
New preclinical work links metformin’s metabolic effects to the brain, showing it acts in the hypothalamus via the Rap1 pathway to enhance central insulin signaling and reduce liver glucose production in mice. This brain-first mechanism could reshape diabetes and obesity therapies, informing drug combinations and trial endpoints, but human validation is needed and questions remain about dosing, blood–brain barrier crossing, and interactions with AMPK.
Researchers have discovered that metformin, a common diabetes drug, also acts in the brain, specifically in the ventromedial hypothalamus, by turning off the protein Rap1, which is essential for its blood sugar-lowering effects. This finding suggests new avenues for more targeted diabetes treatments and highlights the brain's role in metformin's mechanism of action.